| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD23 |
| Uniprot No | P06734 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 48-321aa |
| 氨基酸序列 | DTTQSLKQLE ERAARNVSQV SKNLESHHGD QMAQKSQSTQ ISQELEELRA EQQRLKSQDL ELSWNLNGLQ ADLSSFKSQE LNERNEASDL LERLREEVTK LRMELQVSSG FVCNTCPEKW INFQRKCYYF GKGTKQWVHA RYACDDMEGQ LVSIHSPEEQ DFLTKHASHT GSWIGLRNLD LKGEFIWVDG SHVDYSNWAP GEPTSRSQGE DCVMMRGSGR WNDAFCDRKL GAWVCDRLAT CTPPASEGSA ESMGPDSRPD PDGRLPTPSA PLHS |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD23重组蛋白的3篇参考文献示例(注：以下文献为示例性内容，非真实存在)：
---
1. **文献名称**：*Structural Characterization of Recombinant Human CD23 and Its Interaction with IgE*
**作者**：Smith, J. et al.
**摘要**：通过重组表达技术获得人源CD23胞外域蛋白，利用X射线晶体学解析其三维结构，揭示了CD23与IgE-Fc段的结合位点，为靶向过敏反应的药物设计提供结构基础。
2. **文献名称**：*Soluble CD23 Enhances B-Cell Proliferation and IgE Synthesis in Allergic Disorders*
**作者**：Chen, L. et al.
**摘要**：研究重组可溶性CD23(sCD23)在体外对B细胞活化的调控作用，发现其通过结合CD21受体促进IgE合成，提示sCD23在过敏性疾病中的病理机制。
3. **文献名称**：*Recombinant CD23 as a Diagnostic Marker for B-Cell Chronic Lymphocytic Leukemia*
**作者**：Müller, R. et al.
**摘要**：开发基于重组CD23蛋白的ELISA检测方法，验证其在B细胞慢性淋巴细胞白血病患者血清中的高表达水平，证明其作为潜在诊断标志物的临床价值。
---
**说明**：以上文献摘要围绕CD23重组蛋白的结构解析、功能机制及临床应用展开，涵盖基础研究与转化方向。实际研究中建议通过PubMed或Web of Science检索关键词“recombinant CD23”、“soluble CD23”获取真实文献。
**Background of Recomcombinant CD23 Protein**
CD23. also known as the low-affinity immunoglobulin epsilon Fc receptor (FcεRII), is a type II transmembrane glycoprotein primarily expressed on B lymphocytes, macrophages, and other antigen-presenting cells. It plays a dual role in immune regulation, functioning both as a receptor for immunoglobulin E (IgE) and a mediator of IgE-dependent processes. Structurally, CD23 contains a C-type lectin domain at its extracellular C-terminus, which facilitates interactions with IgE, and a conserved N-terminal cytoplasmic tail involved in intracellular signaling. Alternative splicing generates two isoforms: membrane-bound CD23 (mCD23) and soluble CD23 (sCD23), both implicated in modulating allergic responses, inflammation, and IgE homeostasis.
Recombinant CD23 protein is engineered in vitro using expression systems (e.g., mammalian or insect cells) to produce purified forms of the protein for research and therapeutic applications. Its production enables detailed study of CD23-ligand interactions, particularly with IgE, and its role in pathologies such as allergic asthma, atopic dermatitis, and autoimmune disorders. Dysregulated CD23 expression is also linked to B-cell malignancies, highlighting its potential as a diagnostic or therapeutic target.
In drug development, recombinant CD23 aids in screening inhibitors for allergic diseases or designing monoclonal antibodies to block IgE binding. Additionally, sCD23’s immunomodulatory effects—such as promoting B-cell survival and cytokine release—are explored in autoimmune and inflammatory disease models. Despite progress, challenges remain in understanding CD23’s context-dependent signaling and optimizing its therapeutic targeting. Ongoing research continues to unravel its complex biology, positioning recombinant CD23 as a critical tool for advancing immunology and precision medicine.
×
